Tocilizumab |
Catalog No.GC37809
One-Click Copy Product Info
|
Tocilizumab is a recombinant humanized, anti-human monoclonal antibody directed against interleukin 6 receptors (IL-6R).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 375823-41-9
Sample solution is provided at 25 µL, 10mM.
Tocilizumab is a recombinant humanized, anti-human monoclonal antibody directed against interleukin 6 receptors (IL-6R)[1]. Tocilizumab inhibits the binding of IL-6 to the related receptors, and thus reduces the cytokines pro-inflammatory activity by competing for both the soluble and membrane-bound forms of the IL-6R[2]. Tocilizumab has been widely used in arthritis research to inhibit the acute-phase response[3].
In vitro, Tocilizumab incubated (10ng/ml) for 30 minutes significantly reduced the IL-6-induced phosphorylation level of STAT3 in U937 cells[4]. Tocilizumab treatment (30µg/ml) for 24 hours inhibited the expression of IL-8 and the phosphorylation level of NF-κB in MDA-MB-231 cells[5]. Treatment with 100ng/ml Tocilizumab for 24 hours suppressed the proliferation of A549, H1299 and H358 cells, and induced cell cycle arrest as well as apoptosis[6].
In vivo, Tocilizumab administration via intrathecal injection at a dose of 10μg/day for 28 days improved motor function in mice after spinal cord injury (SCI), promoted the repair of tight junctions between vascular endothelial cells, and inhibited the formation of fibrotic scars[7]. A single intraperitoneal injection of Tocilizumab at a dose of 4mg/kg mitigated cecal ligation and puncture(CLP)-caused lung injury within 22 hours, and reduced oxidative stress and inflammatory response[8].
References:
[1] Scott L J. Tocilizumab: a review in rheumatoid arthritis[J]. Drugs, 2017, 77(17): 1865-1879.
[2] Sheppard M, Laskou F, Stapleton P P, et al. Tocilizumab (actemra)[J]. Human vaccines & immunotherapeutics, 2017, 13(9): 1972-1988.
[3] Sebba A. Tocilizumab: the first interleukin-6-receptor inhibitor[J]. American Journal of Health-System Pharmacy, 2008, 65(15): 1413-1418.
[4] Merbl Y, Lopez Baltazar J M, Byron M, et al. Tocilizumab binds to canine IL-6 receptor and elicits in-vitro inhibitory biological response[J]. Frontiers in Veterinary Science, 2025, 12: 1645414.
[5] Alraouji N N, Aboussekhra A. Tocilizumab inhibits IL‐8 and the proangiogenic potential of triple negative breast cancer cells[J]. Molecular Carcinogenesis, 2021, 60(1): 51-59.
[6] Kim N H, Kim S K, Kim D S, et al. Anti-proliferative action of IL-6R-targeted antibody tocilizumab for non-small cell lung cancer cells[J]. Oncology letters, 2015, 9(5): 2283-2288.
[7] Luo Y, Yao F, Shi Y, et al. Tocilizumab promotes repair of spinal cord injury by facilitating the restoration of tight junctions between vascular endothelial cells[J]. Fluids and Barriers of the CNS, 2023, 20(1): 1.
[8] Zhu J, Lin X, Yan C, et al. Tocilizumab attenuates acute lung injury in rats with sepsis by regulating S100A12/NLRP3[J]. American Journal of Translational Research, 2023, 15(1): 99.
| Cell experiment [1]: | |
|
Cell lines |
A549 cells |
|
Preparation Method |
A549 cells were cultured in RPMI-1640 medium, supplemented 10% heat-inactivated fetal bovine serum and 1% penicillin/streptomycin at 37°C in an incubator with 5% CO2. Cells were seeded in a 6-well plate at a density of 2.5×105 cells/well overnight. Cells were treated with 100ng/ml Tocilizumab for 24h, and apoptosis and cell morphology analysis were conducted. |
|
Reaction Conditions |
100ng/ml; 24h |
|
Applications |
Tocilizumab treatment induced apoptosis in A549 cells, accompanied by morphological changes in the apoptotic cells, including shrinkage, rounding and membrane blebbing. |
| Animal experiment [2]: | |
|
Animal models |
Female C57BL/6J mice |
|
Preparation Method |
Female C57BL/6J mice (18-22g) were bred with the appropriate temperature and humidity under a 12h light and darkness cycle, and food and water were readily available. The mice were anaesthetized by intraperitoneal injection of 50mg/kg pentobarbital sodium. The T10 segment of the spinal cord was exposed after laminectomy. The severe crush SCI model was established by clamping the spinal cord at the T10 level for 5s from two sides. The appearance of a clear red clamp trace at the spinal cord clamping site and the vigorous swinging of the lower limbs and tail of the mouse indicated that the model was successfully established. The lamina was removed from mice in the sham group without clamping the spinal cord. The incisions were closed carefully layer by layer. Anti-infection and auxiliary urination nursing were performed twice a day after SCI. Tocilizumab was diluted with phosphate buffered saline (PBS) to a concentration of 1µg/µl. Immediately after injury, 10µl diluted Tocilizumab was intrathecally injected via a microsyringe. The insertion site was in the dorsal midline of the lumbar 5-6 intervertebral space. Successful insertion into the intrathecal space was confirmed by observing an evident tail flick. The PBS group was injected with the same volume of human IgG in PBS. Injections were performed once a day for 28 days. The injured spinal cord tissue containing the injured core (5mm) was removed for analysis. |
|
Dosage form |
10μg/day; 28 days; i.t. |
|
Applications |
Tocilizumab treatment inhibited inflammation and fibrotic scarring, and promoted axon regeneration in injured spinal cord tissue of mice. |
References: [1] Kim N H, Kim S K, Kim D S, et al. Anti-proliferative action of IL-6R-targeted antibody tocilizumab for non-small cell lung cancer cells[J]. Oncology letters, 2015, 9(5): 2283-2288. [2] Luo Y, Yao F, Shi Y, et al. Tocilizumab promotes repair of spinal cord injury by facilitating the restoration of tight junctions between vascular endothelial cells[J]. Fluids and Barriers of the CNS, 2023, 20(1): 1. | |
| Cas No. | 375823-41-9 | SDF | |
| Canonical SMILES | [Tocilizumab] | ||
| Formula | M.Wt | ||
| Solubility | Soluble in water | Storage | Store at -80°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
-
Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 15 reference(s) in Google Scholar.)